Inferra AI / Company / CYRX

Cryoport, Inc.

CYRX · Health Care

Last earnings Aug 6, 2026

Key results

Revenuequarter

16%

revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Life Sciences Services revenuequarter

18%

Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Growthquarter

up 16%

Jerrell Shelton, CEO of Cryoport, commented, “Cryoport delivered a strong start to 2026 with first-quarter revenue of $47.8 million, up 16% year-over-year, reflecting a continuation of our momentum over the past several quarters across our integrated services and products platform.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Revenue in support of commercial Cell and Gene Therapies (CGT) grew 26% to $9.1 million, while clinical trial support revenue grew 18% to $12.9 million.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

“Our Life Sciences Services segment delivered another strong quarter, with revenue increasing 18% year-over-year, including 21% growth in BioStorage/BioServices.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

“Our Life Sciences Products segment also performed very well, generating 15% revenue growth, driven by global demand for MVE Biological Solutions’ cryogenic systems.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

BioLogistics Solutions revenuequarter

17%

BioLogistics Solutions revenue increased 17% year-over-year in Q1 2026, driven by increasing customer activity, continued commercial product maturation, and clinical advancement within the CGT market.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

AI analysis

Q1 2026 · reported May 4, 2026

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Headline figures

Metric	Q1 2026	Prior qtr	Year ago
Revenue	16%	—	—
Life Sciences Services revenue	18%	—	—
Growth	up 16%	—	—
BioLogistics Solutions revenue	17%	—	—

EX-99 · May 4, 2026

Guidance · company-stated

Direction: Raised

Revenue$192 million

“Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million,” concluded Mr.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

In November 2024, the FASB issued ASU 2024-04 , Debt Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which clarifies the assessment of whether certain settlements of convertible debt instruments should be accounted for as an inducement conversion or extinguishment of convertible debt.

Accounting Guidance Issued but Not Adopted at June 30, 2026 In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock, which provides guidance regarding the initial measurement of paid-in-kind ( PIK ) dividends on preferred stock classified as permanent or temporary equity.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Cryoport, Inc. — Earnings release (2026-05-04)

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million,” concluded Mr.”

Revenue — Raised (“increased”)
“Reflecting on our strong performance in the first quarter and increased visibility into the remainder of the year, we are raising our full-year revenue guidance to $192 million to $196 million,” concluded Mr.”

Classified from the release's primary full-year outlook statement.

Capital allocation

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The amendments require that PIK dividends be initially measured based on the PIK dividend rate stated in the preferred stock agreement, such as multiplying a stated dividend rate by the liquidation value of the preferred stock outstanding, rather than at fair value.

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, unvested restricted stock units and shares associated with the conversion of the Company s 0.75 % Convertible Senior Notes due in 2026 (the 2026 Convertible Senior Notes ) and the Company s 4.0 % Series C Convertible Preferred Stock ( Series C Preferred Stock ) outstanding during the periods, using the treasury stock method or the if converted method as applicable.

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The following table shows the Company s gross unrealized losses and fair value of available-for-sale debt securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2026 (in thousands): Less than 12 Months 12 Months or More Total Unrealized Unrealized Unrealized Fair Value Losses Fair Value Losses Fair Value Losses U.

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Strategy & priorities

These strategic investments expand our global footprint in key geographies and further strengthen our ability to support the advancement and commercialization of life-saving therapies globally.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

3 Financial Highlights On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group as part of a strategic partnership.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Forward-looking statements also include those related to the Company’s expectations about future benefits relating to the CRYOPDP divestiture and strategic partnership with DHL (collectively, the “DHL Transaction”), the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s plans and expectations relating to its strategic pivot to expand its global partnerships, and the Company’s expectation of revenue contribution from IntegriCell’s cryopreservation service centers throughout 2026.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Cryoport Investor Contacts: Todd Fromer / Scott Eckstein KCSA Strategic Communications cryoport@kcsa.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Risks & headwinds

Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, tariffs and other trade restrictions, foreign currency fluctuations, trends in the products markets, any U.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Additional risks and uncertainties relating to the DHL Transaction include, but are not limited to, the risk that any disruption resulting from the DHL Transaction may adversely affect our businesses and business relationships, including with employees and suppliers.

SEC original ↗Cryoport, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Legal Proceedings 37 ITEM 1A.

SEC original ↗Cryoport, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Documents

Earnings deck slides

0 decks with slide view

Cryoport, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors